Michael Schmitz
Stock Analyst at Guggenheim
(2.62)
# 2,166
Out of 5,044 analysts
9
Total ratings
66.67%
Success rate
14.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Neutral | $109 → $97 | $94.89 | +2.22% | 3 | Sep 30, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $29.13 | +47.61% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $40.08 | +12.29% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $58.17 | +40.97% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $9.50 | +321.05% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.49 | - | 1 | Jan 3, 2023 |
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109 → $97
Current: $94.89
Upside: +2.22%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $29.13
Upside: +47.61%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $40.08
Upside: +12.29%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $58.17
Upside: +40.97%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $9.50
Upside: +321.05%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -